Free Trial

Acumen Pharmaceuticals (ABOS) News Today

Acumen Pharmaceuticals logo
$1.05 +0.07 (+7.37%)
Closing price 04:00 PM Eastern
Extended Trading
$1.03 -0.02 (-1.81%)
As of 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Equities Analysts Set Expectations for ABOS FY2029 Earnings
Acumen Pharmaceuticals, Inc. stock logo
What is HC Wainwright's Forecast for ABOS FY2029 Earnings?
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Stock analysts at HC Wainwright issued their FY2029 earnings per share estimates for Acumen Pharmaceuticals in a research report issued to clients and investors on Friday, March 28th. HC Wainwright analyst A. Fein anticipates that the com
Acumen Pharmaceuticals, Inc. stock logo
UBS Group Lowers Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target to $4.00
UBS Group cut their price objective on Acumen Pharmaceuticals from $6.00 to $4.00 and set a "buy" rating on the stock in a research report on Friday.
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Lowered to $11.00 at HC Wainwright
HC Wainwright lowered their target price on shares of Acumen Pharmaceuticals from $15.00 to $11.00 and set a "buy" rating for the company in a research note on Friday.
Q4 2024 Acumen Pharmaceuticals Inc Earnings Call
Acumen price target lowered to $11 from $15 at H.C. Wainwright
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals (NASDAQ:ABOS) Posts Quarterly Earnings Results
Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.15).
Acumen completes enrollment of ALTITUDE-AD Phase 2 trial
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals (ABOS) Projected to Post Earnings on Tuesday
Acumen Pharmaceuticals (NASDAQ:ABOS) will be releasing earnings before the market opens on Tuesday, March 25, Financial Modeling Prep reports.
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Price Down 4% - Here's What Happened
Acumen Pharmaceuticals (NASDAQ:ABOS) Trading Down 4% - Here's Why
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the target of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 1,560,000 shares, an increase of 9.1% from the December 31st total of 1,430,000 shares. Currently, 3.5% of the shares of the company are short sold. Based on an average trading volume of 276,000 shares, the short-interest ratio is currently 5.7 days.
Promising US Penny Stocks To Consider In January 2025
Acumen Pharmaceuticals, Inc. stock logo
Matt Zuga Sells 28,902 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 28,902 shares of Acumen Pharmaceuticals stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $1.72, for a total value of $49,711.44. Following the sale, the chief financial officer now directly owns 231,744 shares in the company, valued at $398,599.68. The trade was a 11.09 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 12,619 Shares
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 12,619 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.59, for a total value of $20,064.21. Following the completion of the transaction, the chief executive officer now directly owns 667,488 shares of the company's stock, valued at approximately $1,061,305.92. This represents a 1.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Acumen Pharmaceuticals, Inc. stock logo
Equities Analysts Offer Predictions for ABOS FY2025 Earnings
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Acumen Pharmaceuticals in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Large Growth in Short Interest
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,560,000 shares, an increase of 9.1% from the December 15th total of 1,430,000 shares. Currently, 3.5% of the shares of the stock are sold short. Based on an average trading volume of 276,000 shares, the short-interest ratio is currently 5.7 days.
Acumen announces Phase 1 INTERCEPT-AD study publication
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) COO Sells 7,636 Shares
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) COO Russell Barton sold 7,636 shares of the business's stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $1.86, for a total value of $14,202.96. Following the transaction, the chief operating officer now owns 89,231 shares in the company, valued at approximately $165,969.66. This trade represents a 7.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Insider Eric Siemers Sells 10,859 Shares
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) insider Eric Siemers sold 10,859 shares of the company's stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $1.85, for a total value of $20,089.15. Following the sale, the insider now owns 106,717 shares of the company's stock, valued at $197,426.45. This represents a 9.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Acumen Pharmaceuticals, Inc. stock logo
Matt Zuga Sells 13,235 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 13,235 shares of the company's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $1.84, for a total transaction of $24,352.40. Following the completion of the transaction, the chief financial officer now owns 198,210 shares of the company's stock, valued at approximately $364,706.40. The trade was a 6.26 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Sells $87,911.52 in Stock
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 47,778 shares of the firm's stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $1.84, for a total value of $87,911.52. Following the completion of the transaction, the chief executive officer now owns 454,707 shares in the company, valued at approximately $836,660.88. This represents a 9.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 5.4% in November
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the target of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,390,000 shares, a decrease of 5.4% from the November 15th total of 1,470,000 shares. Based on an average daily volume of 202,200 shares, the short-interest ratio is currently 6.9 days. Currently, 3.1% of the shares of the stock are short sold.
Remove Ads
Get Acumen Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.

ABOS Media Mentions By Week

ABOS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ABOS
News Sentiment

0.51

0.64

Average
Medical
News Sentiment

ABOS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ABOS Articles
This Week

6

2

ABOS Articles
Average Week

Remove Ads
Get Acumen Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ABOS) was last updated on 4/7/2025 by MarketBeat.com Staff
From Our Partners